The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder.

被引：0
|
作者：
Dash, A [1 ]
Koppie, T [1 ]
Vora, K [1 ]
Bochner, B [1 ]
Galsky, MD [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399S / 399S
页数：1
相关论文
共 50 条
  • [1] Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder
    Dash, Atreya
    Galsky, Matthew D.
    Vickers, Andrew J.
    Serio, Angel M.
    Koppie, Theresa M.
    Dalbagni, Guido
    Bochner, Bernard H.
    [J]. CANCER, 2006, 107 (03) : 506 - 513
  • [2] Intravesical gemcitabine (G) single agent as adjuvant chemotherapy in superficial transitional cell carcinoma (TCC) of bladder.
    Bouzid, K
    Ferhat, R
    Bounedjar, A
    Mahfouf, H
    Smaili, F
    Adjali, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 407S - 407S
  • [3] Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder
    Botten, Joanne
    Sephton, Matt
    Tillett, Tania
    Masson, Susan
    Thanvi, Narottam
    Herbert, Christopher
    Hilman, Serena
    Rowe, Edward
    Gillatt, David
    Persad, Raj
    Whittlestone, Tim
    Bahl, Amit
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [4] ELIGIBILITY OF PATIENTS WITH UROTHELIAL CANCER OF THE BLADDER FOR NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY
    Vemana, Goutham
    Sandhu, Gurdarshan
    Nepple, Kenneth
    Strope, Seth
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E54 - E54
  • [5] Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients
    Thompson, R. Houston
    Boorjian, Stephen A.
    Kim, Simon P.
    Cheville, John C.
    Thapa, Prabin
    Tarrel, Robert
    Dronca, Roxana
    Costello, Brian
    Frank, Igor
    [J]. BJU INTERNATIONAL, 2014, 113 (5B) : E17 - E21
  • [6] Validity of renal function eligibility criteria for cisplatin-based chemotherapy for patients with urothelial carcinoma.
    Hi, Sai
    Naito, Yushi
    Hattori, Kyosuke
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 638 - 638
  • [7] ELIGIBILITY FOR NEOADJUVANT/ADJUVANT CISPLATIN-BASED CHEMOTHERAPY AMONG RADICAL CYSTECTOMY PATIENTS
    Thompson, R. Houston
    Boorjian, Stephen
    Kim, Simon
    Cheville, John
    Thapa, Prabin
    Tarrel, Robert
    Frank, Igor
    [J]. JOURNAL OF UROLOGY, 2013, 189 (04): : E529 - E529
  • [8] Paclitaxel, carboplatin and gemcitabine (PCG) as neoadjuvant therapy in patients with locally advanced transitional cell carcinoma (TCC) of the bladder.
    Smith, DC
    Bhandari, M
    Hussain, M
    Montie, JE
    Wood, DP
    Lee, CT
    Petrylak, DP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 392S - 392S
  • [9] The EMI study: A regional feasibility study for a randomised trial of adjuvant chemotherapy following definitive treatment for transitional cell cancer (TCC) of the bladder.
    Leahy, MG
    Brown, J
    Jones, WG
    Kelly, J
    Neal, DE
    Prescott, S
    Roberts, T
    Selby, P
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 : S3 - S3
  • [10] The EMI study: A regional feasibility study for a randomised trial of adjuvant chemotherapy following definitive treatment for transitional cell cancer (TCC) of the bladder.
    Leahy, MG
    Brown, J
    Jones, WG
    Kelly, J
    Neal, DE
    Prescott, S
    Roberts, T
    Selby, P
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 : S23 - S23
12345